Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 187Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Hematologic Neoplasms 98Leukemia, Lymphocytic, Chronic, B-Cell 88Myelodysplastic Syndromes 72Leukemia 63Lymphoma 45Multiple Myeloma 40Lymphoma, Non-Hodgkin 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Burkitt Lymphoma 28Neoplasms 25Recurrence 23Leukemia, Myelomonocytic, Chronic 23Myeloproliferative Disorders 21Lymphoma, Large B-Cell, Diffuse 20Hodgkin Disease 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia, Biphenotypic, Acute 18Lymphoma, Mantle-Cell 17Leukemia, B-Cell 17Lymphoma, B-Cell 15Lymphoma, Follicular 14Waldenstrom Macroglobulinemia 13Anemia, Refractory, with Excess of Blasts 13Myelodysplastic-Myeloproliferative Diseases 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Hairy Cell 9Blast Crisis 9Primary Myelofibrosis 8

Interventions

rasburicase 1Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tumor Lysis Syndrome × Other hematologic neoplasm × 30 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡